MetaCap

XBiotech (XBIT) vs Xilio Therapeutics (XLO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

XBiotech (XBIT) has outperformed Xilio Therapeutics (XLO) over the past year, losing 24.1% versus a loss of 28.3%. Over five years, XBIT leads with a -86.5% price change compared with -97.3% for XLO. Xilio Therapeutics is the larger company by market cap ($53.4 million vs $52.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

XBIT-24.12%XLO-28.29%
+21%-7%-35%
Nov 21, 20251 yearNov 20, 2026
XBIT-86.35%XLO-97.63%
+6%-48%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

XBIT versus XLO key metrics
MetricXBITXLO
Share price$1.73$7.56
Market cap$52.74M$53.40M
1-day change+2.98%-1.11%
YTD return-27.62%-15.63%
1-year return-24.12%-28.29%
5-year return-86.48%-97.29%
P/E ratio (TTM)—11.63
Forward P/E13.31—
EPS (TTM)$-1.43$0.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$43.77M
Revenue growth (YoY)—+589.88%
Net income (latest FY)$-45.54M$-35.04M
Operating margin—-95.92%
Net margin—-80.05%
52-week high$2.73$10.71
52-week low$1.61$6.47
Distance from 52-week high-36.63%-29.41%
Analyst consensus—none
Avg. price target upside—+164.55%
Average volume64.77K11.54K
Shares outstanding30.49M7.06M
Employees8776
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About XBiotech

XBIT stock →

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

About Xilio Therapeutics

XLO stock →

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

XBIT vs XLO FAQ

Which is bigger, XBiotech or Xilio Therapeutics?

Xilio Therapeutics (XLO) is larger, with a market capitalization of $53.40M compared with $52.74M for XBiotech (XBIT).

Which stock has performed better over the past year, XBIT or XLO?

XBIT returned -24.12% over the past 12 months, compared with -28.29% for XLO (price return, excluding dividends). Past performance does not predict future results.

Are XBiotech and Xilio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons